Once daily controlled-release pregabalin significantly improved time to loss of therapeutic response vs. placebo in patients with fibromyalgia, a study presented at the 2013 ACR/ARHP Annual Meeting concluded.
ACR/ARHP Annual Meeting 2013
Patients with rheumatoid arthritis and diabetes mellitus had no increase in mean fasting blood glucose levels after 3 months of treatment with tofacitinib, a novel oral Janus kinase inhibitor, according to a pooled analysis of five phase 3 trials reported at the 2013 ACR/ARHP Annual Meeting.
Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.
Isoniazid treatment for latent tuberculosis infection (LTBI) in patients with rheumatoid arthritis (RA) who started TNF inhibitors is associated with the occurrence of liver function abnormality, according to investigators at the 2013 ACR/ARHP Annual Meeting.
Lidocaine and triamcinolone hexacetonide injected intra-articularly in interphalangeal joints reduced swelling and pain during movement in the hands of patients with osteoarthritis, results of a randomized, double-blind trial presented at the 2013 ACR/ARHP Annual Meeting concluded.
At the 2013 ACR/ARHP Annual Meeting, study researchers presented that the investigational, lower-dose diclofenac submicron particle capsules were generally well-tolerated in patients with osteoarthritis.
Patients with hip or knee osteoarthritis who received subcutaneous tanezumab reported improvements in pain and physical function at all doses studied, results presented at the 2013 ACR/ARHP Annual Meeting have shown.
Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.
At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.
Do tumor necrosis factor inhibitors (TNFi) improve HbA1c in patients with rheumatoid arthritis? The answer depends on the agent and on whether patients have diabetes mellitus, according to a study presented at the 2013 ACR/ARHP Annual Meeting.
Want to read more?
Please login or register first to view this content.